medpace holdings inc - MEDP

MEDP

Close Chg Chg %
669.20 7.58 1.13%

Closed Market

676.77

+7.58 (1.13%)

Volume: 306.53K

Last Updated:

Oct 26, 2026, 4:00 PM EDT

Company Overview: medpace holdings inc - MEDP

MEDP Key Data

Open

$671.46

Day Range

663.61 - 678.23

52 Week Range

373.00 - 684.52

Market Cap

$18.25B

Shares Outstanding

27.91M

Public Float

22.72M

Beta

1.18

Rev. Per Employee

N/A

P/E Ratio

36.27

EPS

$18.36

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

335.00K

 

MEDP Performance

1 Week
 
1.13%
 
1 Month
 
9.35%
 
3 Months
 
12.54%
 
1 Year
 
11.83%
 
5 Years
 
198.73%
 

MEDP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About medpace holdings inc - MEDP

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: North America, Europe, Asia, South America, Africa and Australia. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

MEDP At a Glance

Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, Ohio 45227
Phone 1-513-579-9911 Revenue 2.53B
Industry Miscellaneous Commercial Services Net Income 451.12M
Sector Commercial Services 2025 Sales Growth 19.97%
Fiscal Year-end 12 / 2026 Employees 6,200
View SEC Filings

MEDP Valuation

P/E Current 36.265
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 36.761
Price to Sales Ratio 6.554
Price to Book Ratio 34.625
Price to Cash Flow Ratio 23.25
Enterprise Value to EBITDA 28.813
Enterprise Value to Sales 6.412
Total Debt to Enterprise Value 0.008

MEDP Efficiency

Revenue/Employee 408,102.258
Income Per Employee 72,761.774
Receivables Turnover 6.293
Total Asset Turnover 1.241

MEDP Liquidity

Current Ratio 0.736
Quick Ratio 0.736
Cash Ratio 0.37

MEDP Profitability

Gross Margin 28.95
Operating Margin 21.142
Pretax Margin 21.436
Net Margin 17.829
Return on Assets 22.134
Return on Equity 70.235
Return on Total Capital 75.702
Return on Invested Capital 59.183

MEDP Capital Structure

Total Debt to Total Equity 29.811
Total Debt to Total Capital 22.965
Total Debt to Total Assets 6.928
Long-Term Debt to Equity 24.755
Long-Term Debt to Total Capital 19.07
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medpace Holdings Inc - MEDP

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.46B 1.89B 2.11B 2.53B
Sales Growth
+27.80% +29.17% +11.84% +19.97%
Cost of Goods Sold (COGS) incl D&A
1.05B 1.39B 1.48B 1.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
40.36M 26.33M 29.25M 28.12M
Depreciation
37.00M 24.13M 27.81M 27.18M
Amortization of Intangibles
3.35M 2.20M 1.44M 946.00K
COGS Growth
+25.69% +32.17% +6.80% +21.30%
Gross Income
410.10M 498.18M 627.05M 732.49M
Gross Income Growth
+33.57% +21.48% +25.87% +16.82%
Gross Profit Margin
+28.09% +26.42% +29.73% +28.95%
2022 2023 2024 2025 5-year trend
SG&A Expense
131.40M 161.35M 180.18M 197.56M
Research & Development
- - - -
-
Other SG&A
131.40M 161.35M 180.18M 197.56M
SGA Growth
+21.19% +22.79% +11.67% +9.64%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
278.70M 336.82M 446.87M 534.93M
Non Operating Income/Expense
7.07M (655.00K) 29.05M 7.44M
Non-Operating Interest Income
- - - 25.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 2.90M 488.00K
-
Interest Expense Growth
- - +2,666.67% -83.20%
-
Gross Interest Expense
- - 2.90M 488.00K
-
Interest Capitalized
- - - -
-
Pretax Income
282.86M 335.68M 475.92M 542.38M
Pretax Income Growth
+40.13% +18.67% +41.78% +13.96%
Pretax Margin
+19.37% +17.80% +22.57% +21.44%
Income Tax
37.49M 52.87M 71.54M 91.25M
Income Tax - Current - Domestic
57.15M 73.23M 92.28M 2.29M
Income Tax - Current - Foreign
3.33M 4.62M 5.88M 8.05M
Income Tax - Deferred - Domestic
(23.00M) (25.99M) (25.54M) 82.05M
Income Tax - Deferred - Foreign
13.00K 1.01M (1.08M) (1.13M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (157.00K) (191.00K) (44.00K)
Consolidated Net Income
245.21M 282.62M 404.34M 451.12M
Minority Interest Expense
- - - -
-
Net Income
245.21M 282.62M 404.34M 451.12M
Net Income Growth
+35.18% +15.26% +43.07% +11.57%
Net Margin Growth
+16.80% +14.99% +19.17% +17.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
245.21M 282.62M 404.34M 451.12M
Preferred Dividends
- - - -
-
Net Income Available to Common
245.21M 282.62M 404.34M 451.12M
EPS (Basic)
7.571 9.1992 13.0614 15.639
EPS (Basic) Growth
+49.68% +21.51% +41.98% +19.73%
Basic Shares Outstanding
32.39M 30.72M 30.96M 28.85M
EPS (Diluted)
7.2826 8.876 12.6302 15.2783
EPS (Diluted) Growth
+51.35% +21.88% +42.30% +20.97%
Diluted Shares Outstanding
33.67M 31.84M 32.01M 29.53M
EBITDA
319.05M 363.15M 476.12M 563.06M
EBITDA Growth
+35.18% +13.82% +31.11% +18.26%
EBITDA Margin
+21.85% +19.26% +22.58% +22.25%

Snapshot

Average Recommendation HOLD Average Target Price 667.667
Number of Ratings 16 Current Quarters Estimate 4.834
FY Report Date 12 / 2026 Current Year's Estimate 18.242
Last Quarter’s Earnings 4.84 Median PE on CY Estimate N/A
Year Ago Earnings 15.28 Next Fiscal Year Estimate 19.696
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 9 12 12
Mean Estimate 4.83 4.70 18.24 19.70
High Estimates 4.95 5.03 18.68 20.35
Low Estimate 4.77 4.50 18.14 19.13
Coefficient of Variance 1.22 3.90 0.80 1.97

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 12 12 11
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Medpace Holdings Inc - MEDP

Date Name Shares Transaction Value
Oct 12, 2026 Susan E. Burwig Exec. VP, Operations 67,984 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $166.73 per share 11,334,972.32
Oct 12, 2026 Susan E. Burwig Exec. VP, Operations 6,028 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 30, 2026 August James Troendle President & CEO; Director 389,302 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $620.6 per share 241,600,821.20
Sep 30, 2026 August James Troendle President & CEO; Director 386,892 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $620.07 per share 239,900,122.44

Medpace Holdings Inc in the News